for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evotec SE

EVTG.DE

Latest Trade

29.54EUR

Change

0.11(+0.37%)

Volume

387,720

Today's Range

29.09

 - 

29.68

52 Week Range

17.17

 - 

31.00

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
29.43
Open
29.33
Volume
387,720
3M AVG Volume
13.40
Today's High
29.68
Today's Low
29.09
52 Week High
31.00
52 Week Low
17.17
Shares Out (MIL)
151.20
Market Cap (MIL)
4,824.01
Forward P/E
205.23
Dividend (Yield %)
--

Next Event

Evotec SE at Life Sciences Partners BioCapital Europe Conference (Virtual)

Latest Developments

More

Evotec Partners With Alloy Therapeutics To Expand Its Antibody Discovery Platform

Evotec Achieves Milestones In Its Collaboration With Bristol Myers Squibb

Evotec And Sartorius Partner With Start-Up Curexsys

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Industry

Biotechnology & Drugs

Contact Info

Essener Bogen 7

22419

Germany

+49.40.560810

https://www.evotec.com/

Executive Leadership

Wolfgang Plischke

Independent Chairman of the Supervisory Board

Werner Lanthaler

Chief Executive Officer, Member of the Management Board

Iris Loew-Friedrich

Independent Vice Chairman of the Supervisory Board

Enno Spillner

Chief Financial Officer, Member of the Management Board

Craig Johnstone

Chief Operating Officer, Member of the Management Board

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.3K

2018

0.4K

2019

0.4K

2020(E)

0.5K
EPS (EUR)

2017

0.160

2018

0.470

2019

0.250

2020(E)

0.141
Price To Earnings (TTM)
311.96
Price To Sales (TTM)
9.94
Price To Book (MRQ)
9.41
Price To Cash Flow (TTM)
253.04
Total Debt To Equity (MRQ)
96.17
LT Debt To Equity (MRQ)
90.05
Return on Investment (TTM)
1.39
Return on Equity (TTM)
1.19

Latest News

Latest News

Evotec secures grant to evaluate antibody drugs for COVID-19

German biotech company Evotec <EVTG.DE> said on Monday it had received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody (mAbS) drugs for the prevention of severe COVID-19.

BRIEF-Evotec Acquires Site From Sanofi, No Financial Terms Disclosed

* EVOTEC ACQUIRES SITE FROM SANOFI AND SECURES CAPACITY FOR LONG-TERM GROWTH

BRIEF-Evotec, Samsara Biocapital And KCK In Strategic Collaboration

* AUTOBAHN LABS CREATES JOINTLY-OWNED NEW COMPANIES AND INVESTS UP TO $ 5 M PER PROJECT. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Evotec Subsidiary Cyprotex Awarded New 5 Year Agreement With US EPA

* EVOTEC: CYPROTEX AWARDED NEW 5 YEAR AGREEMENT WITH US ENVIRONMENTAL PROTECTION AGENCY ('EPA') Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-N4 Pharma Says Evotec To Move To Second Phase Of Work On COVID-19 Project

* N4 PHARMA PLC- EVOTEC WILL NOW MOVE TO SECOND PHASE OF WORK Source text for Eikon: Further company coverage:

BRIEF-Evotec Sees No Material Impact From Covid-19, Confirms Guidance

* EVOTEC SE REPORTS FIRST QUARTER 2020 RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Evotec Announces Collaboration To Develop Covid-19 Antibodies

* SUBSIDIARY JUST EVOTEC BIOLOGICS HAS ENTERED INTO A PARTNERSHIP WITH OLOGY BIO FOR EVALUATION AND ANALYTICAL CHARACTERISATION OF ANTIBODIES AGAINST SARS-COV-2

BRIEF-Evotec Regains Global Rights To Beta Cell Replacement Therapy

* DGAP-NEWS: EVOTEC REGAINS GLOBAL RIGHTS TO BETA CELL REPLACEMENT THERAPY

BRIEF-Evotec Enters Nanomedicine Through Partnership With Leon-Nanodrugs

* DGAP-NEWS: EVOTEC ENTERS NANOMEDICINE THROUGH STRATEGIC PARTNERSHIP WITH LEON-NANODRUGS

BRIEF-Evotec Enters Gene Therapy Alliance with Takeda, No Financial Details Given

* EVOTEC AND TAKEDA ENTER INTO MULTI-YEAR GENE THERAPY RESEARCH ALLIANCE

BRIEF-Evotec Establishes Gene Therapy Research And Development Site In Austria

* EVOTEC ESTABLISHES GENE THERAPY RESEARCH AND DEVELOPMENT SITE WITH MORE THAN 20 EXPERIENCED SCIENTISTS IN AUSTRIA Further company coverage: (Berlin Speed Desk)

BRIEF-Evotec Reaches Licensing Agreement With Canada's Pancella

* EVOTEC EXPANDS ITS IPSC-BASED CELL THERAPY PLATFORM EVOCELLS THROUGH LICENSING AGREEMENT WITH PANCELLA

BRIEF-Evotec And South Korea's Ildong Collaborate On Indigo Platform

* DGAP-NEWS: EVOTEC AND ILDONG TO COLLABORATE WITH DEVELOPMENT PROJECTS ON INDIGO PLATFORM

BRIEF-Evotec Expects 2020 EBITDA at last year's level between 100 to 120 Mln Eur

* DGAP-NEWS: EVOTEC SE FISCAL YEAR 2019 RESULTS: EXCELLENT 2019 PERFORMANCE; VERY GOOD OUTLOOK FOR CONTINUED GROWTH 2020

BRIEF-Evotec's Partner Forge Announces Collaboration With Roche On Novel Antibiotic

* EVOTEC'S PARTNER FORGE THERAPEUTICS, INC. ('FORGE') TODAY ANNOUNCED A RESEARCH COLLABORATION AND OPTION AGREEMENT WITH HOFFMANN-LA ROCHE LTD. ('ROCHE') TO LICENSE ONE OF ITS NOVEL ANTIBIOTICS FOR TREATMENT OF HOSPITAL-BASED LUNG INFECTIONS.

BRIEF-Evotec Says Co Maintains All Operations Despite Virus

* WE HAVE SURVEYED OUR SUPPLY CHAIN AND ARE ACTIVELY MANAGING SUPPLIES TO MAINTAIN BUSINESS CONTINUITY

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP

BRIEF-Evotec Says Endometriosis Programme With Bayer Moves To Phase I Development

* DGAP-NEWS: EVOTEC AND BAYER ADVANCE THIRD ENDOMETRIOSIS PROGRAMME INTO PHASE I CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage:

BRIEF-Evotec AG Says ‍Plans Conversion Into European Company​

* SAYS PLANS CONVERSION INTO EUROPEAN COMPANY Source text for Eikon: Further company coverage: (Reporting by Frankfurt Newsroom)

Sanofi, Evotec team up for research on infectious diseases treatment

Sanofi and Evotec said they had started exclusive talks over accelerating research into the treatment of infectious diseases, and added on Thursday that they would form a new open innovation platform in this area, led by Evotec.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up